Physician profile
Paul Rexroth
NPI 1811995681
$452.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $37.99 · 2021: $121 · 2022: $63.26.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98.25 | 2019-2022 | |
| Novo Nordisk INC | $97.05 | 2019-2022 | |
| Abbvie INC. | $89.63 | 2021-2022 | |
| Lilly USA, LLC | $27.90 | 2019 | |
| Pfizer INC. | $27.81 | 2019-2020 | |
| Amarin Pharma, INC. | $27.56 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.12 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $20.11 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.02 | 2019 | |
| Nabriva Therapeutics, Plc | $12.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.24 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Rexroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.